Patents Assigned to BIOGEN IDEC INTERNATIONAL NEUROSCIENCE GMBH
  • HUMAN ANTI-TAU ANTIBODIES
    Publication number: 20150252102
    Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
    Type: Application
    Filed: November 4, 2014
    Publication date: September 10, 2015
    Applicants: UNIVERSITY OF ZURICH, BIOGEN IDEC INTERNATIONAL NEUROSCIENCE GMBH
    Inventors: ROGER NITSCH, FENG CHEN, JAN GRIMM, JEAN-LUC BAERISWYL, CHRISTOPH HOCK
  • HUMAN ANTI-ALPHA-SYNUCLEIN ANTIBODIES
    Publication number: 20150232542
    Abstract: Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.
    Type: Application
    Filed: January 8, 2015
    Publication date: August 20, 2015
    Applicants: Biogen Idec International Neuroscience GmbH, University of Zurich
    Inventors: Andreas WEIHOFEN, Jan Grimm, Roger Nitsch, Christoph Hock
  • Human anti-tau antibodies
    Patent number: 8940272
    Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
    Type: Grant
    Filed: October 11, 2011
    Date of Patent: January 27, 2015
    Assignees: University of Zurich, Biogen Idec International Neuroscience GmbH
    Inventors: Roger Nitsch, Feng Chen, Jan Grimm, Jean-Luc Baeriswyl, Christoph Hock
  • Human anti-alpha-synuclein antibodies
    Patent number: 8940276
    Abstract: Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: January 27, 2015
    Assignees: Biogen Idec International Neuroscience GmbH, University of Zurich
    Inventors: Andreas Weihofen, Jan Grimm, Roger Nitsch, Christoph Hock
  • Anti-Alpha Synuclein Binding Molecules
    Publication number: 20140369940
    Abstract: Provided are anti-human ?-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human ?-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human ?-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.
    Type: Application
    Filed: June 22, 2012
    Publication date: December 18, 2014
    Applicants: University of Zurich, Biogen IDEC International Neuroscience GmbH
    Inventors: Andreas Weihofen, Jan Grimm, Cristoph Hock, Roger Nitsch, Lihe Su, Paul Weinreb
  • USE OF AN ANTI-alpha-SYNUCLEIN ANTIBODY TO DIAGNOSE AN ELEVATED LEVEL OF alpha-SYNUCLEIN IN THE BRAIN
    Publication number: 20140295465
    Abstract: This disclosure relates to the use of anti-?-synuclein antibody to diagnose an elevated level of ?-synuclein in the brain. Specifically, the disclosure relates to the method of assessing the levels of ?-synuclein in a blood plasma or CSF following administration to the test subject of an anti-?-synuclein antibody or antigen-binding fragment thereof, which can bind ?-synuclein with sufficient activity to alter the net efflux of ?-synuclein from brain to blood, or from brain to CSF.
    Type: Application
    Filed: October 29, 2012
    Publication date: October 2, 2014
    Applicant: BIOGEN IDEC INTERNATIONAL NEUROSCIENCE GMBH
    Inventors: Andreas Weihofen, Thomas Engber, Jan Grimm